Literature DB >> 3071458

Comparison of ketanserin with captopril in older hypertensives. A double-blind randomised trial.

P Meyer1, M Safar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3071458     DOI: 10.2165/00003495-198800361-00029

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  9 in total

1.  The acute antihypertensive effect of ketanserin increases with age.

Authors:  J De Crée; M Hoing; M De Ryck; J Symoens
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

2.  Effect of ketanserin in the treatment of patients with intermittent claudication: results from 13 placebo-controlled parallel group studies.

Authors:  D L Clement; D Duprez
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

3.  Ketanserin compared to nifedipine and methyldopa in patients aged above 50 years: two international multicentre studies. For the International Study Group.

Authors:  M Janssens; J Symoens
Journal:  J Hypertens Suppl       Date:  1986-12

Review 4.  Can peripheral serotonergic blockade explain the hypotensive effect of ketanserin?

Authors:  P M Vanhoutte
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

5.  Hemodynamic response to chronic ketanserin treatment in essential hypertension.

Authors:  R Fagard; R Fiocchi; P Lijnen; J Staessen; A Amery
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

6.  Ketanserin in the treatment of mild hypertension in elderly patients: preliminary results of a controlled double-blind trial.

Authors:  G Dona; A Ribeiro; A E Tammaro
Journal:  J Hypertens Suppl       Date:  1986-04

7.  Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension.

Authors:  L M Wing; J P Chalmers; M J West; A J Bune; B Ayres; J R Graham
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

8.  Ketanserin in the acute management of severe hypertension.

Authors:  B F Murphy; J A Whitworth; P Kincaid-Smith
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

Review 9.  Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.

Authors:  R J Cody
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

  9 in total
  3 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Quality of life as a therapeutic end-point. An analysis of therapeutic trials in hypertension.

Authors:  N K Hollenberg; M Testa; G H Williams
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

3.  Ketanserin and captopril interaction in the treatment of essential hypertensives.

Authors:  G Lavezzaro; P E Ladetto; M Valente; D Stramignoni; C Zanna; G Assogna; A Salvetti
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.